Skip Navigation


European Heart Journal Advance Access originally published online on February 19, 2009
European Heart Journal 2009 30(6):640-641; doi:10.1093/eurheartj/ehp066
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/6/640    most recent
ehp066v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tendera, M.
Right arrow Articles by Wojakowski, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tendera, M.
Right arrow Articles by Wojakowski, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Cell therapy—success does not come easy

Michal Tendera* and Wojciech Wojakowski

3rd Division of Cardiology, Medical University of Silesia, 40-120 635 Katowice, Poland

* Corresponding author. Tel: +48 32 353 9543, Fax: +48 32 353 9543, Email: michal.tendera@gmail.com or michal.tendera@gcm.pl

This editorial refers to ‘Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study’{dagger}, by L. Herbots et al., on page 662

The first 10% of the full text of this article appears below.

More than 6 years ago the initial report on clinical application of bone marrow-derived mononuclear cells (BMMNCs) in patients with acute myocardial infarction (AMI) opened up a new era of regenerative cardiology and brought with it great enthusiasm and expectations.1 Since then, numerous clinical trials have been carried out with the aim of assessing the efficacy and safety of stem cell therapy. In all cases the safety of the therapy was proved, but its effectiveness still remains a matter of controversy and fierce debate.2

Since stem cell therapy trials in patients with AMI began, the primary outcome measure has been the change in left ventricular (LV) ejection fraction (EF). The LV volumes have also been analysed to assess more accurately the cause . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study
Lieven Herbots, Jan D'hooge, Elif Eroglu, Daisy Thijs, Javier Ganame, Piet Claus, Christophe Dubois, Koen Theunissen, Jan Bogaert, Joseph Dens, Maria Kalantzi, Steven Dymarkowski, Bart Bijnens, Ann Belmans, Marc Boogaerts, George Sutherland, Frans Van de Werf, Frank Rademakers, and Stefan Janssens
EHJ 2009 30: 662-670. [Abstract] [Full Text]